In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus : a multicenter study in China
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf331 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Rongqi Lu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beiji…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Staphylococcus, Enterococcus, Oxazolidinones. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research, Special Foundation for National Science and Technology Basic Research Program.
Abstract (Originalsprache)
Objective
To evaluate the in vitro activity of contezolid against clinical Staphylococcus and Enterococcus isolates from across China, and compare its performance with linezolid and other key agents.
Methods
A total of 2510 non-duplicate Gram-positive cocci isolates were collected from 70 hospitals in seven Chinese regions. Minimum inhibitory concentrations (MICs) were determined using broth microdilution (BMD) per CLSI guidelines. MIC50/90 values, susceptibility rates, cumulative MIC curves and MIC distribution agreement between contezolid and linezolid were assessed. Linezolid-resistant isolates and contezolid-resistant isolates—defined as those based on CLSI 2025 linezolid breakpoints—underwent whole-genome sequencing and comprehensive screening for known oxazolidinone resistance determinants, including acquired resistance genes, 23S rRNA mutations and amino acid substitutions in ribosomal proteins L3, L4 and L22.
Results
Contezolid exhibited potent in vitro activity, with >99% of isolates inhibited at ≤4 mg/L and showed lower MIC50/90 than linezolid, with a consistently left-shifted cumulative MIC distribution. Cohen’s kappa analysis supporting enhanced activity of contezolid. Notably, we report for the first time clinical isolates with contezolid MICs up to 16 mg/L. Whole-genome analysis of 14 linezolid-resistant isolates (including five resistant to contezolid) revealed universal presence of optrA, cfr, fexA and other resistance genes, alongside domain V 23S rRNA mutations and substitutions in ribosomal proteins L3 and L4, supporting a shared genetic basis and potential cross-resistance between the two agents.
Conclusions
Contezolid demonstrated potent and consistent activity against drug-resistant Gram-positive cocci, supporting its potential as a therapeutic alternative to linezolid. Further studies are needed to confirm resistance mechanisms and clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
ORCID-Profile: Rongqi Lu
Förderung
- National High Level Hospital Clinical Research
- Special Foundation for National Science and Technology Basic Research Program
Zitieren
APA
Lu, R., Li, X., Yang, W., Chen, J., Zhang, G., Li, J., Zhang, J., Wang, T., Kang, W., Gao, H., Xu, Y., & Liu, Y. (2025). In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus : a multicenter study in China. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf331
Vancouver
Lu R, Li X, Yang W, Chen J, Zhang G, Li J, et al. In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus : a multicenter study in China. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf331
BibTeX
@article{Lu2025,
author = {Lu, Rongqi and Li, Xue and Yang, Wenhang and Chen, Jiawei and Zhang, Ge and Li, Jin and Zhang, Jingjia and Wang, Tong and Kang, Wei and Gao, Haotian and Xu, Yingchun and Liu, Yali},
title = {In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus : a multicenter study in China},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf331}
}
EUVIMED